What changed
$PFE — BUY 📊 | 6 MONTHS THESIS
🎯 Q1 2026 | Rev $14.5B | EPS $0.75 vs $0.72 🟢
💡 Consensus assumes persistent COVID revenue decline and assigns a low multiple (~9x P/E) reflecting terminal decline fears. The variant view sees ex-COVID revenue growth sustaining mid-single digits, driving EPS beats and a re-rating toward 12x P/E, in line with large pharma peers post-patent-cliff stabilization.
📉 Reward/risk: 3.93:1
🏢 Business Quality: 7/10 - Large, diversified pharma with strong cash flows and R&D engine; however, faces material patent cliffs and high debt load, limiting upside vs. higher-growth peers.
📊 Valuation: cheap on forward P/E (8.9x vs. 12–14x peer/historical range) and attractive FCF yield (5.98% annualized). Fair on EV/EBITDA (~12x estimated).
🔮 Catalyst: Q2 2026 earnings release (expected late July 2026)
📊 Our read: BUY. Full analysis →
https://stockduty.xyz/s/PFE0611